Document is current
Any future updates will be listed below
-
Authors
Pattalachinti, Vinay K. https://orcid.org/0009-0007-7293-0548
Haque, Emaan
Yousef, Mahmoud https://orcid.org/0009-0007-2550-4837
Yousef, Abdelrahman
Chowdhury, Saikat https://orcid.org/0000-0002-0783-3959
Overman, Michael
Parseghian, Christine M.
Morris, Van K.
Kee, Bryan
Huey, Ryan W. https://orcid.org/0000-0002-7887-8484
Raghav, Kanwal https://orcid.org/0000-0003-1311-4173
Court, Colin M.
Shen, John Paul https://orcid.org/0000-0003-4588-2775
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K22 CA234406, P30 CA016672)
Cancer Prevention and Research Institute of Texas (RR180035, RP240392)
- License Information
-
More Information
Article History
Received: 17 July 2024
Accepted: 21 January 2025
First Online: 5 February 2025
Competing interests
: J.P.S.—Scientific Advisory Board for Engine Biosciences, NaDeNo Nanoscience; Research funding from BostonGene, Celsius Therapeutics. All other authors declare no COI. M.O.—Consultant for Roche, BMS, Medimmune, Merck, Amgen, Takeda, Janssen, Pfizer, Array, Gritstone, 3DMed, Nouscom, Atreca, Bayer; Research funding from Takeda, Roche, Lilly, Merck, Medimmune, BMS, Nouscom, Phanes.
